Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
12 December 2020 |
Main ID: |
NCT01784419 |
Date of registration:
|
03/02/2013 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients
|
Scientific title:
|
Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients |
Date of first enrolment:
|
October 2013 |
Target sample size:
|
10 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT01784419 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Screening. Masking: Triple (Participant, Care Provider, Investigator).
|
Phase:
|
N/A
|
|
Countries of recruitment
|
United States
| | | | | | | |
Contacts
|
Name:
|
Dennis W Nielson, MD, PhD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
University of California, San Francisco |
| | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Two mutations known to cause cystic fibrosis and a sweat chloride concentration
greater than or equal to 55 mmol
- Greater than or equal to 6 years of age
Exclusion Criteria:
- Homozygous F508del with a sweat chloride greater than 85 mmol
- Taking medication known to interact with ivacaftor and chooses not to discontinue that
medication
- Is pregnant or planning to become pregnant during the study period
- Less than 6 years of age
Age minimum:
6 Years
Age maximum:
N/A
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
Cystic Fibrosis
|
Intervention(s)
|
Drug: ivacaftor
|
Drug: Placebo
|
Primary Outcome(s)
|
Sweat Chloride Concentration
[Time Frame: 14 +/- 2 days]
|
Secondary Outcome(s)
|
Spirometry
[Time Frame: 14 +/- 2 days]
|
Multibreath Washout Testing
[Time Frame: 14 +/- 2 days]
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
|